

October 18, 2018

Dr. 2

US Nuclear Regulatory Commission, Region I
2100 Renaissance Boulevard, Suite 100
King of Prussia, PA 19406-2713

Subject: Closure of Radiopharmacy at Leidos Biomedical Research (License number 19-21091-01) / 03019755

The purpose of this letter is to notify your outfit of the closure of the Radiopharmacy at Leidos Biomedical Research Inc. (Leidos) in accordance with the Code of Maryland Regulations (COMAR 10.34.14.04). An attachment is included with this letter that provides the Radiopharmacy's current standing with the Maryland Board of Pharmacy.

The leadership of Leidos has been advised through Mr. Christopher March, the Human Resources Director, on August 22, 2018 to notify your outfit in accordance with 10 CFR 35.14 regarding the discontinuation of performance of duties of the Authorized Nuclear Pharmacist (ANP) / Pharmacist-in-Charge (PIC) beginning September 7, 2018.

Thank you



Dr. George Afari
Former ANP/PIC, Radiopharmacy, Leidos

13048 Open Hearth Way
Germantown MD 20874

Phone: 240 817 6622

Email: georgeafari@msn.com

REC RG 1 10 23 18 AM 06:58

cc: Mr. Christopher March, Human Resource Director, Leidos

cc: Mr. J.T. Moore, Radiation Safety Officer, Leidos

610304

Details

Demographic Information

Name: LEIDOS BIOMEDICAL RESEARCH INC

Address Information

Address: 1050 BOYLES STREET, BLDG 459

RM 154 -156

City: Frederick

State: MD

Zip: 21702

Maryland License\Permit Information

Number: PW0348

Type: Pharmacy Waiver

Status: Closed

**Original
Issued:** 3/24/2011

**Date
Renewed:** 5/15/2018

Expires: 5/31/2020

Specialty Information

Specialty: LEGACY UNKNOWN EST

Related Documents



ACKNOWLEDGEMENT - RECEIPT OF CORRESPONDENCE

Name and Address of Applicant and/or Licensee Leidos Biomedical Research, Inc. ATTN: Kathy Teresky, Chief Operating Officer NCI Campus at Frederick P. O. Box B Frederick, MD 21702-1201	Date October 24, 2018
	License Number(s) 19-21091-01
	Mail Control Number(s) 610304
	Licensing and/or Technical Reviewer or Branch Commercial, Industrial, R&D, & Academic Branch

This is to acknowledge receipt of your: Letter and/or Application Dated: 10/18/2018

The initial processing, which included an administrative review, has been performed.
 Amendment Termination New License Renewal

There were no administrative omissions identified during our initial review.

This is to acknowledge receipt of your application for renewal of the material(s) license identified above. Your application is deemed timely filed, and accordingly, the license will not expire until final action has been taken by this office.

Your application for a new NRC license did not include your taxpayer identification number. Please complete and submit NRC Form 531, Request for Taxpayer Identification Number, located at the following link: <http://www.nrc.gov/reading-rm/doc-collections/forms/nrc531.pdf>
 Follow the instructions on the form for submission.

The following administrative omissions have been identified:
 [Empty box for listing omissions]

Your application has been assigned the above listed MAIL CONTROL NUMBER. When calling to inquire about this action, please refer to this control number. Your application has been forwarded to a technical reviewer. Please note that the technical review, which is normally completed within 180 days for a renewal application (90 days for all other requests), may identify additional omissions or require additional information. If you have any questions concerning the processing of your application, our contact information is listed below:

Region I
U. S. Nuclear Regulatory Commission
Division of Nuclear Materials Safety
2100 Renaissance Boulevard, Suite 100
King of Prussia, PA 19406-2713
(610) 337-5260, (610) 337-5313,
(610) 337-5398, or (610) 337-5239